Medicinal radiocompounds or radiopharmaceuticals are a group of pharmaceutical drugs which have radioactivity and they can be used as diagnostic and therapeutic agents. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood and tumors, and in therapy for many diseases. Radiopharmaceuticals imply the usage of radiation for non-invasive treatment and diagnosis of various diseases. Utilization of these molecules for medical purposes in PET and SPECT imaging has changed the entire algorithm of disease diagnosis.
The global radiopharmaceuticals market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the indications (cardiovascular, oncology, neurological, thyroid, gastrointestinal, etc.), therapeutics (systemic oncology using Iodine, Yttrium, Samarium, Strontium, Rhenium, Lutetium, Erbium; cardiology, neurology, etc.), technologies (SPECT – Technetium, Thallium, Gallium, Iodine, Rhenium, Yttrium; PET – Fludeoxyglucose, Rubidium, Carbon-11 Choline, Nitrogen-13 Ammonia, etc.), generators (Mo-99/Tc-99m, Sr-82/Rb-82, Ge-68/Ga-68, Sr-90/Y-90, and W-188/Re-188 generators), end users (diagnostic centers, hospitals and medical centers), and forecasts growth trends (CAGR% – 2017 to 2021).
The global radiopharmaceuticals market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global radiopharmaceuticals market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global radiopharmaceuticals market and included in this report are Cardinal Health Inc., Covidien Plc, GE Healthcare, IBA Group, Lantheus Medical Imaging, Monrol Nuclear Products, Inc., Nordion, Inc., NTP Radioisotopes Ltd., Polatom, Positron Corporation, and Siemens Healthcare.